Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01915511 · ClinicalTrials.gov registry record
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
A clinical trial of Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, sponsored by Duke University.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 20
- Study locations
NCT01915511: Recruiting study of Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, sponsored by Duke University.
NCT01915511 is a study of Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease that is actively recruiting participants, run by Duke University. The registered enrollment target is 3,000 participants. The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01915511, a study of Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.
Primary Outcome
Characterize and describe the natural history of patients with a recent confirmed diagnosis of IPF, with emphasis on demographics, co-morbidities, medications, and risks for disease progression or death.
Conditions Studied
Study Locations (20)
California
- University of California - Los Angeles - Los Angeles
- University of Southern California - Los Angeles
- Stanford University - Stanford
Illinois
- University of Chicago - Chicago
- Northwestern University - Evanston
- Loyola University Health System - Maywood
Florida
- University of Florida - Gainesville
- University of South Florida - Tampa
Georgia
- Emory University - Atlanta
- Piedmont Healthcare - Austell
Alabama
- University of Alabama - Birmingham - Birmingham
Arizona
- University of Arizona - Tucson
Connecticut
- Yale University - New Haven
Kansas
- University of Kansas - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2014-06 |
| Est. Completion | 2031-01 |
What NCT01915511 shows while recruiting
NCT01915511 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease appearing as the primary indexed condition, and to 0 interventions.
NCT01915511 names 20 study sites across 14 states, led by California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT01915511 about?
NCT01915511 is a clinical study titled "Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry". The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with...
What is the current status of trial NCT01915511?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2014-06. Estimated completion is 2031-01.
What conditions does trial NCT01915511 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease.
Who is sponsoring clinical trial NCT01915511?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01915511 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia